Researchers from RMIT University, MIT, and Harvard Medical School have developed a dissolvable polymer-based printing ink that preserves the structure of mRNA-LNP motifs during the drying process. According to the study published in Advanced Functional Materials, this method stabilizes vaccine components for room-temperature storage, potentially eliminating the need for traditional cold-chain logistics.
How do polymer-based patches stabilize mRNA?
The stability of mRNA-carrying particles depends on the specific interaction between the nanoparticle design and the concentration of the polymer used in the patch. Dr. Brendan Dyett of RMIT University noted that the team analyzed how these particles respond to drying and rehydration cycles. By identifying the precise formulation conditions that maintain biological activity, the researchers can ensure that the mRNA remains functional after the ink is printed and dried into a microneedle array.
What are the primary logistical benefits of this technology?
Current mRNA vaccine distribution relies on energy-intensive cold-chain logistics, which increases both the financial cost and the complexity of global delivery. Lead researcher Calum Drummond AO stated that this research builds a foundation for microneedle patches that make advanced therapies more accessible. By allowing for stable, dry-state storage, the technology could reduce the infrastructure requirements currently needed to transport heat-sensitive medical products to remote or underserved regions.
How does this compare to other drug delivery innovations?
The potential for microneedle technology extends beyond vaccines. In previous research, Daewoong Pharmaceutical demonstrated a microneedle patch for the delivery of the obesity drug semaglutide. According to that study, the patch achieved the highest reported bioavailability results to date for the GLP drug semaglutide. While the RMIT and MIT team is currently focused on mRNA-LNP motifs, the findings suggest that the underlying polymer-based ink technology could eventually be adapted for a wide variety of therapeutic molecules.
Future applications of mRNA-LNP printing
The research team plans to continue optimizing both the nanoparticle architecture and the patch formulations. Because lipid nanoparticles (LNPs) are increasingly recognized as critical excipients for mRNA delivery, the researchers believe their findings will have applications in medicine far beyond standard vaccine development. The focus remains on refining the ink’s composition to ensure maximum efficacy across different types of genetic payloads.
Frequently Asked Questions
Can these patches be stored at room temperature?
Yes. The study shows that the polymer-based ink protects mRNA-LNP motifs during the drying process, which is a necessary step for enabling room-temperature stability.
What role does the polymer play in the patch?
The polymer acts as a carrier that preserves the structure of the mRNA-carrying particles as they transition from a liquid ink to a dry, solid state within the microneedle patch.
Is this technology limited to vaccines?
No. According to the research team, these vaccine inks and their associated polymers have potential uses in medicine for delivering various types of molecules beyond current vaccine designs.
Are you interested in the future of medical technology? Subscribe to our weekly newsletter to get the latest updates on biotech breakthroughs and drug delivery research delivered straight to your inbox.
